迈瑞医疗：董事长李西廷完成2亿元增持计划

Core Viewpoint - The announcement details the completion of a share buyback plan by the chairman of Mindray Medical, Li Xiting, reflecting confidence in the company's intrinsic value and growth prospects [1] Group 1: Buyback Plan Details - Buyback Entity: Li Xiting, one of the actual controllers and chairman of the company [1] - Total Investment: 200 million RMB (including transaction fees) [1] - Shares Acquired: 1,005,381 shares, representing 0.08% of the company's total equity [1] - Buyback Period: From November 27, 2025, to December 12, 2025, completed ahead of the originally planned six-month period [1] - Method of Acquisition: Centralized bidding transaction [1] - Source of Funds: Li Xiting's personal funds [1] Group 2: Shareholding Structure Changes - Shareholding Before Buyback: Li Xiting and his concerted actor Xu Hang collectively controlled 51.47% of the shares [1] - Shareholding After Buyback: They now control 51.55% of the shares, with no change in the status of the actual controller [1] Group 3: Important Arrangements - Lock-up Period: No reduction in holdings for six months following the completion of the buyback [1] - Purpose of Buyback: Based on recognition of the company's intrinsic value and confidence in its development prospects [1] - Compliance: The buyback complies with relevant regulatory requirements and has received confirmation from a law firm [1]